Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Brain Injury Program
Cholesterol Lowering Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
Company Fact Sheet
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2-Aug-2022
Initial Director's Interest Notice - GM
2-Aug-2022
Final Director's Interest Notice - PM
26-Jul-2022
Quarterly Activities Report and Appendix 4C
20-Jul-2022
Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
29-Jun-2022
Cholesterol-Lowering Program Update
7-Jun-2022
Corporate Presentation
6-Jun-2022
Brain Injury Program Target Unveiled and Phase I Update
17-May-2022
European Patent to be Granted for Cholesterol-Lowering Drug
19-Apr-2022
Nyrada Quarterly Activities Report & Appendix 4C
30-Mar-2022
Investor Roadshow Presentation
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
Next
